Drugless Treatment for Hypertension

Utilizing patented sensor technology, a new device translates a patient's individual breathing patterns into customized musical tones that guide the patient to lengthen the expiratory phase and thus slow breathing to fewer than 10 breaths per minute. After the exercise, breathing returns to normal, but the beneficial effects on blood pressure accumulate. Use of the device for fifteen minutes per day produced an average reduction in blood pressure of 12 mmHg systolic and six mmHg diastolic in just six weeks of treatment. The reduction was greater for older people and for people with higher initial blood pressure. Results were independent of both gender and medication status.

The device, called Resperate, is the product of InterCure, Ltd. (Lod, Israel). The company states that the benefits of the device have been demonstrated in seven clinical trials involving more than 300 patients. The device has been cleared by the US Food and Drug Administration (FDA) for the adjunctive treatment of hypertension.

"The Resperate device provides physicians and patients with a new, much-needed option to further lower blood pressure without adding medications to a patient`s existing routine,” said Dr. Cristina Giannattasio, who conducted one of InterCure`s clinical studies at the University of Milan-Bicocca, Italy. "The majority of the patients enrolled in this study were already taking multiple medications, while still exhibiting uncontrolled blood pressure. With Resperate, we were able to lower their blood pressure significantly with no side effects whatsoever.”




Related Links:
InterCure, Ltd.